These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20668073)

  • 1. Mapping the N-terminal residues of Epstein-Barr virus gp42 that bind gH/gL by using fluorescence polarization and cell-based fusion assays.
    Liu F; Marquardt G; Kirschner AN; Longnecker R; Jardetzky TS
    J Virol; 2010 Oct; 84(19):10375-85. PubMed ID: 20668073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational analyses of Epstein-Barr virus glycoprotein 42 reveal functional domains not involved in receptor binding but required for membrane fusion.
    Silva AL; Omerovic J; Jardetzky TS; Longnecker R
    J Virol; 2004 Jun; 78(11):5946-56. PubMed ID: 15140992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells.
    Bu W; Kumar A; Board NL; Kim J; Dowdell K; Zhang S; Lei Y; Hostal A; Krogmann T; Wang Y; Pittaluga S; Marcotrigiano J; Cohen JI
    Immunity; 2024 Mar; 57(3):559-573.e6. PubMed ID: 38479361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
    Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
    Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition.
    Chen WH; Kim J; Bu W; Board NL; Tsybovsky Y; Wang Y; Hostal A; Andrews SF; Gillespie RA; Choe M; Stephens T; Yang ES; Pegu A; Peterson CE; Fisher BE; Mascola JR; Pittaluga S; McDermott AB; Kanekiyo M; Joyce MG; Cohen JI
    Immunity; 2022 Nov; 55(11):2135-2148.e6. PubMed ID: 36306784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection.
    Liu C; Li S; Qiao M; Zeng C; Liu X; Tang Y
    Arch Virol; 2024 Jul; 169(8):167. PubMed ID: 39020055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus.
    Snijder J; Ortego MS; Weidle C; Stuart AB; Gray MD; McElrath MJ; Pancera M; Veesler D; McGuire AT
    Immunity; 2018 Apr; 48(4):799-811.e9. PubMed ID: 29669253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A gH/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge.
    Edwards KR; Malhi H; Schmidt K; Davis AR; Homad LJ; Warner NL; Chhan CB; Scharffenberger SC; Gaffney K; Hinkley T; Potchen NB; Wang JY; Price J; McElrath MJ; Olson J; King NP; Lund JM; Moodie Z; Erasmus JH; McGuire AT
    NPJ Vaccines; 2024 Jun; 9(1):120. PubMed ID: 38926438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Single Amino Acid Substitution in the Transmembrane Domain of Glycoprotein H Functionally Compensates for the Absence of gL in Pseudorabies Virus.
    Vallbracht M; Schnell M; Seyfarth A; Fuchs W; Küchler R; Mettenleiter TC; Klupp BG
    Viruses; 2023 Dec; 16(1):. PubMed ID: 38257727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent human monoclonal antibodies targeting Epstein-Barr virus gp42 reveal vulnerable sites for virus infection.
    Zhao GX; Fang XY; Bu GL; Chen SJ; Sun C; Li T; Xie C; Wang Y; Li SX; Meng N; Feng GK; Zhong Q; Kong XW; Liu Z; Zeng MS
    Cell Rep Med; 2024 May; 5(5):101573. PubMed ID: 38776874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DQ
    Li Q; Bu W; Gabriel E; Aguilar F; Hoshino Y; Miyadera H; Hess C; Hornung RL; Roy A; Cohen JI
    JCI Insight; 2017 Feb; 2(4):e85687. PubMed ID: 28239644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteins of purified Epstein-Barr virus.
    Johannsen E; Luftig M; Chase MR; Weicksel S; Cahir-McFarland E; Illanes D; Sarracino D; Kieff E
    Proc Natl Acad Sci U S A; 2004 Nov; 101(46):16286-91. PubMed ID: 15534216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge.
    Malhi H; Homad LJ; Wan YH; Poudel B; Fiala B; Borst AJ; Wang JY; Walkey C; Price J; Wall A; Singh S; Moodie Z; Carter L; Handa S; Correnti CE; Stoddard BL; Veesler D; Pancera M; Olson J; King NP; McGuire AT
    Cell Rep Med; 2022 Jun; 3(6):100658. PubMed ID: 35705092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the binding effect and mechanism of glycyrrhizin to ovomucin by combining spectroscopic analysis and molecular docking.
    Shengnan Z; Yingjie Z; Junyue C; Shuangshuang S; Xin L; Yuanyuan S
    Int J Biol Macromol; 2023 Aug; 245():125535. PubMed ID: 37356685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies against EBV gp42 show potent
    Wu Q; Zhong L; Wei D; Zhang W; Hong J; Kang Y; Chen K; Huang Y; Zheng Q; Xu M; Zeng MS; Zeng YX; Xia N; Zhao Q; Krummenacher C; Chen Y; Zhang X
    Emerg Microbes Infect; 2023 Dec; 12(2):2245920. PubMed ID: 37542379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Generation and Immunogenicity Analysis of EBV gp42 N-Terminal Region.
    Hong J; Wei D; Wu Q; Zhong L; Chen K; Huang Y; Zhang W; Chen J; Xia N; Zhang X; Chen Y
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kaposi Sarcoma-Associated Herpesvirus Glycoprotein H Is Indispensable for Infection of Epithelial, Endothelial, and Fibroblast Cell Types.
    Muniraju M; Mutsvunguma LZ; Foley J; Escalante GM; Rodriguez E; Nabiee R; Totonchy J; Mulama DH; Nyagol J; Wussow F; Barasa AK; Brehm M; Ogembo JG
    J Virol; 2019 Aug; 93(16):. PubMed ID: 31142670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human MHC-II with Shared Epitope Motifs Are Optimal Epstein-Barr Virus Glycoprotein 42 Ligands-Relation to Rheumatoid Arthritis.
    Trier N; Izarzugaza J; Chailyan A; Marcatili P; Houen G
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29361739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies.
    Sathiyamoorthy K; Jiang J; Möhl BS; Chen J; Zhou ZH; Longnecker R; Jardetzky TS
    Proc Natl Acad Sci U S A; 2017 Oct; 114(41):E8703-E8710. PubMed ID: 28939750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for Epstein-Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins.
    Sathiyamoorthy K; Hu YX; Möhl BS; Chen J; Longnecker R; Jardetzky TS
    Nat Commun; 2016 Dec; 7():13557. PubMed ID: 27929061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.